FDA
-
-
-
-
-
-
-
Baudax Bio Announces Distribution of Series C Preferred Stock to Holders of its Common Stock
-
-
-
-
-
-
-
Baudax Bio Reports 2022 Fourth Quarter and Annual Financial Results and Provides Business Update
-
-
-
-
-
-
-
Baudax Bio receives notice of allowance for U.S. Patent Application covering use of ANJESO® for the treatment of moderate to severe pain
-
-
-
-
-
-
-
Baudax Bio (BXRX) Granted Seventh Orange Book Listable Patent for ANJESO
-
-
-
-
-
-
-
Baudax Bio Reports Third Quarter 2021 Financial Results and Business Highlights
-
-
-
-
-
-
-
Baudax Bio Reports First Quarter 2021 Financial Results
-
-
-
-
-
-
-
Baudax Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
322,086 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

